Compare Amphastar Pharmaceuticals Inc (AMPH) vs Okta, Inc. (OKTA) Price & Performance

AMPH trades at $18.72, down 1.58% with bearish technical signals despite oversold RSI readings. The company reported mixed Q1 2026 results with EPS of $0.42 missing estimates of $0.70, continuing a trend of recent earnings disappointments. Valuation metrics appear reasonable with P/E of 11.29 and P/B of 1.07, while profitability remains solid with 47.34% gross margins. Recent news includes a Zacks Strong Sell rating and ongoing securities law investigation.

The stock faces near-term headwinds from earnings misses and negative analyst sentiment, though current valuations provide some downside protection. Upside potential exists if the company can execute its strategic pivot to proprietary drugs and biosimilars while managing BAQSIMI discount pressures. Key risks include ongoing legal scrutiny and competitive pressures in the generic drug market.

OKTA trades at $138.63, down 6.86% today, but maintains strong technical momentum with bullish moving averages and recent AI-driven demand boosting cybersecurity stocks. The company shows improving fundamentals with revenue growth to $2.61B in 2025 and three consecutive quarterly EPS beats. Positive sentiment is driven by AI security adoption and institutional interest, though high valuations (P/E 100.46) and overbought RSI levels warrant caution.

Outlook remains positive with AI security demand accelerating revenue growth and improving profitability (2026 net margin projected at 8.24%). Key risks include intense cybersecurity competition and valuation concerns. Analyst consensus is strongly bullish (73% buy ratings) with $124.08 price target, though current price exceeds consensus suggesting near-term consolidation potential.